Medications
Why weight loss medication is long-term treatment, and what really happens if you stop
Stopping Wegovy or Mounjaro usually brings most of the weight back. Here is why it happens.
Well Revolution
August 26, 2026
What the trials show about stopping, regain, and the better options in between
Most people start a weight loss injection quietly hoping it will be temporary. Lose the weight, stop the medicine, move on. It is a completely understandable hope, and it is worth knowing from day one what the evidence says about it, because the pattern is one of the most consistent findings in modern obesity research: when the medication stops, most of the weight comes back, and the health gains go with it.
That is not a reason for despair, and it is definitely not a personal failing. It is how a chronic condition behaves. Understanding it early is the difference between a plan that works for years and a frustrating cycle of loss and regain.
Your body defends its heaviest weight
Obesity was formally defined as a chronic, relapsing disease by the 2025 Lancet Commission, and the biology behind that label is well established. When you lose weight, your body does not celebrate. It responds as if food has become scarce: hunger hormones rise, fullness signals weaken, and energy use drops. Researchers measured these hormonal shifts a year after weight loss and found they were still active, still pushing towards regain.
Clinicians sometimes call this the set point: the weight range your body has learned to defend, anchored near your heaviest weight. Losing weight does not reset it. This is why people who have dieted hard their whole lives describe the same pattern of losing weight and regaining it plus a little more. Their bodies are not broken, and they are not weak. They are running ancient software in a modern food environment.
The medicines change the game because they act on the same appetite hormone system, turning down the signals that drive regain. But they only do that while they are in your system.
What the trials show about stopping
The withdrawal data across both medicines tells one story:
- Semaglutide (Wegovy). In the STEP 1 trial extension, people who stopped semaglutide after about 68 weeks regained roughly two thirds of the weight they had lost within the following year. Blood pressure, blood sugar and inflammation markers rose again alongside the weight.
- Semaglutide, continued versus stopped. In STEP 4, everyone started on semaglutide for 20 weeks and lost about 10 percent. Those who continued lost a further 7.9 percent over the next 48 weeks. Those switched to placebo regained about 7 percent in the same period.
- Tirzepatide (Mounjaro). In SURMOUNT-4, after 36 weeks of treatment and around 21 percent weight loss, people switched to placebo regained about 14 percent of their body weight over the following year, while those who continued lost more.
Notably, everyone in these trials also received ongoing lifestyle support with diet and exercise. Even with that support in place, stopping the medicine led to substantial regain for most people. Some individuals do hold their loss after stopping, and they tend to be people who have built strong eating, activity and sleep foundations, but they are the exception rather than the rule.
Why stop-start cycles cost more than they seem
There is a hidden price to repeatedly losing and regaining weight. During weight loss, some of what you lose is muscle and bone, especially without enough protein and strength training. During rapid regain, what returns is mostly fat. Cycle through that a few times and you can end up at the same weight as before but with less muscle, weaker bones and a higher body fat percentage: worse off than when you started.
This is why we encourage members to treat starting medication as a considered, long-term decision, and to talk to us before stopping rather than after.
The good news: long-term does not mean maximum dose forever
Here is the part that changes the conversation. Long-term treatment does not mean staying on the highest dose for life.
The SURMOUNT-MAINTAIN trial, published in The Lancet in 2026, was the first study designed specifically to test what happens after you reach your goal. People lost weight on tirzepatide for 60 weeks, then were randomised to continue their full dose, drop to a low 5 mg maintenance dose, or stop. A year later, those on the full dose were 21.9 percent below their starting weight, those on the reduced dose held 16.6 percent, and those who stopped were back to 9.9 percent below baseline, with two thirds of them regaining enough that the trial restarted their medication.
In other words: a lower dose held most of the result. Maintenance is now an evidence-backed phase of treatment, with room to tailor the dose to you. Some people also hold their loss with longer gaps between doses, guided by their prescriber.
And realistically, treatment is not frozen in time. Prices are shifting as more medicines reach the market, and new options are in development. The long-term plan you build today will have more choices in a few years, not fewer.
What this means for your plan
- Go in with a years-long view: a weight loss phase, then a maintenance phase you plan together with your doctor.
- Build the habits that trials wrapped around the medicine: protein, strength work, regular meals, sleep. They are what make a lower maintenance dose realistic. Our guide to getting the best results on Wegovy or Mounjaro covers all five.
- If cost or side effects mean you do need to stop, tell us first. Stopping with a plan, with your nutrition and strength foundations in place and a re-contact threshold agreed, protects far more of your result than stopping cold.
- If weight starts returning, reach out early. We would much rather hear from you at 3 kg of regain than at 15, because early regain often has a fixable cause: undereating, a nutrient deficiency, poor sleep, a stressful season, or simply a dose that needs adjusting.
This article is general information, not personal medical advice. Decisions about starting, changing or stopping medication always belong with you and your prescriber.
Existing members: questions about your dose or your long-term plan? Log in at member.wellrevolution.com and start a priority chat.
Thinking about treatment? Start an online assessment with one of our NZ-registered doctors.
References
- Rubino F, et al. Definition and diagnostic criteria of clinical obesity. The Lancet Diabetes and Endocrinology. 2025;13(3):221-262. Link
- Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011;365:1597-1604. Link
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. Link
- Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. Link
- Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. Link
- Horn DB, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. Published online 12 May 2026. Link
- Dulloo AG, et al. How dieting makes the lean fatter: from a perspective of body composition autoregulation. Obesity Reviews. 2015;16(Suppl 1):25-35. Link
- Rubino F, et al. Joint international consensus statement for ending stigma of obesity. Nature Medicine. 2020;26:485-497. Link
Seeing a doctor is as easy as sending a text
Concerned, need advice, a prescription, refill or referral?
Chat with a GP now
Subscribe to our newsletter
